nodes	percent_of_prediction	percent_of_DWPC	metapath
Dabigatran etexilate—F2—liver cancer	0.479	1	CbGaD
Dabigatran etexilate—UGT2B7—Epirubicin—liver cancer	0.128	0.462	CbGbCtD
Dabigatran etexilate—UGT1A9—Sorafenib—liver cancer	0.119	0.427	CbGbCtD
Dabigatran etexilate—F2—posterior vena cava—liver cancer	0.0208	0.286	CbGeAlD
Dabigatran etexilate—ABCB1—Sorafenib—liver cancer	0.0192	0.0693	CbGbCtD
Dabigatran etexilate—F2—hepatic artery—liver cancer	0.0184	0.253	CbGeAlD
Dabigatran etexilate—F2—portal vein—liver cancer	0.016	0.22	CbGeAlD
Dabigatran etexilate—ABCB1—Doxorubicin—liver cancer	0.0117	0.042	CbGbCtD
Dabigatran etexilate—Gastritis erosive—Epirubicin—liver cancer	0.00684	0.086	CcSEcCtD
Dabigatran etexilate—Gastritis erosive—Doxorubicin—liver cancer	0.00633	0.0795	CcSEcCtD
Dabigatran etexilate—UGT2B15—gall bladder—liver cancer	0.00501	0.0689	CbGeAlD
Dabigatran etexilate—F2—gall bladder—liver cancer	0.00274	0.0377	CbGeAlD
Dabigatran etexilate—CES1—gall bladder—liver cancer	0.00252	0.0346	CbGeAlD
Dabigatran etexilate—Cerebral haemorrhage—Sorafenib—liver cancer	0.0016	0.0201	CcSEcCtD
Dabigatran etexilate—UGT2B15—liver—liver cancer	0.00147	0.0202	CbGeAlD
Dabigatran etexilate—Haematoma—Sorafenib—liver cancer	0.00141	0.0177	CcSEcCtD
Dabigatran etexilate—Haemoglobin decreased—Sorafenib—liver cancer	0.00129	0.0162	CcSEcCtD
Dabigatran etexilate—Injection site haemorrhage—Epirubicin—liver cancer	0.00122	0.0153	CcSEcCtD
Dabigatran etexilate—Injection site haemorrhage—Doxorubicin—liver cancer	0.00113	0.0141	CcSEcCtD
Dabigatran etexilate—UGT1A9—liver—liver cancer	0.00111	0.0153	CbGeAlD
Dabigatran etexilate—Dyspnoea exertional—Epirubicin—liver cancer	0.00108	0.0136	CcSEcCtD
Dabigatran etexilate—Dyspnoea exertional—Doxorubicin—liver cancer	0.001	0.0126	CcSEcCtD
Dabigatran etexilate—Bone disorder—Sorafenib—liver cancer	0.000981	0.0123	CcSEcCtD
Dabigatran etexilate—Gastrooesophageal reflux disease—Sorafenib—liver cancer	0.000981	0.0123	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Sorafenib—liver cancer	0.000937	0.0118	CcSEcCtD
Dabigatran etexilate—Oesophageal ulcer—Epirubicin—liver cancer	0.000898	0.0113	CcSEcCtD
Dabigatran etexilate—UGT2B7—liver—liver cancer	0.000897	0.0123	CbGeAlD
Dabigatran etexilate—CES2—liver—liver cancer	0.000897	0.0123	CbGeAlD
Dabigatran etexilate—Oesophageal ulcer—Doxorubicin—liver cancer	0.000831	0.0104	CcSEcCtD
Dabigatran etexilate—Drug hypersensitivity—Epirubicin—liver cancer	0.000813	0.0102	CcSEcCtD
Dabigatran etexilate—F2—liver—liver cancer	0.000805	0.0111	CbGeAlD
Dabigatran etexilate—NQO2—liver—liver cancer	0.000802	0.011	CbGeAlD
Dabigatran etexilate—Drug hypersensitivity—Doxorubicin—liver cancer	0.000753	0.00945	CcSEcCtD
Dabigatran etexilate—CES1—liver—liver cancer	0.000739	0.0102	CbGeAlD
Dabigatran etexilate—Hepatic function abnormal—Sorafenib—liver cancer	0.000736	0.00925	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Sorafenib—liver cancer	0.00071	0.00891	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Sorafenib—liver cancer	0.000659	0.00828	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Sorafenib—liver cancer	0.000643	0.00808	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Sorafenib—liver cancer	0.000588	0.00738	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Sorafenib—liver cancer	0.000579	0.00728	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Sorafenib—liver cancer	0.000575	0.00723	CcSEcCtD
Dabigatran etexilate—Gastritis—Sorafenib—liver cancer	0.000569	0.00715	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Sorafenib—liver cancer	0.000568	0.00713	CcSEcCtD
Dabigatran etexilate—Dysphagia—Sorafenib—liver cancer	0.000556	0.00698	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Epirubicin—liver cancer	0.000538	0.00676	CcSEcCtD
Dabigatran etexilate—Abdominal discomfort—Sorafenib—liver cancer	0.000533	0.0067	CcSEcCtD
Dabigatran etexilate—Pneumonia—Sorafenib—liver cancer	0.000499	0.00626	CcSEcCtD
Dabigatran etexilate—Transaminases increased—Doxorubicin—liver cancer	0.000498	0.00626	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Sorafenib—liver cancer	0.000496	0.00623	CcSEcCtD
Dabigatran etexilate—Infestation—Sorafenib—liver cancer	0.000496	0.00623	CcSEcCtD
Dabigatran etexilate—Acute coronary syndrome—Sorafenib—liver cancer	0.000489	0.00614	CcSEcCtD
Dabigatran etexilate—Myocardial infarction—Sorafenib—liver cancer	0.000486	0.0061	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Sorafenib—liver cancer	0.000469	0.00589	CcSEcCtD
Dabigatran etexilate—Epistaxis—Sorafenib—liver cancer	0.000468	0.00587	CcSEcCtD
Dabigatran etexilate—Thrombosis—Epirubicin—liver cancer	0.000463	0.00581	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Sorafenib—liver cancer	0.000447	0.00562	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Sorafenib—liver cancer	0.000445	0.00559	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Epirubicin—liver cancer	0.000443	0.00556	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Sorafenib—liver cancer	0.00044	0.00552	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Sorafenib—liver cancer	0.000437	0.00549	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Sorafenib—liver cancer	0.000436	0.00548	CcSEcCtD
Dabigatran etexilate—Thrombosis—Doxorubicin—liver cancer	0.000428	0.00538	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Sorafenib—liver cancer	0.000413	0.00519	CcSEcCtD
Dabigatran etexilate—Haemoptysis—Doxorubicin—liver cancer	0.00041	0.00514	CcSEcCtD
Dabigatran etexilate—Angiopathy—Sorafenib—liver cancer	0.000404	0.00507	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Sorafenib—liver cancer	0.000402	0.00505	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Sorafenib—liver cancer	0.000401	0.00504	CcSEcCtD
Dabigatran etexilate—Malnutrition—Sorafenib—liver cancer	0.000388	0.00487	CcSEcCtD
Dabigatran etexilate—ABCB1—embryo—liver cancer	0.000374	0.00514	CbGeAlD
Dabigatran etexilate—Rectal haemorrhage—Epirubicin—liver cancer	0.000363	0.00455	CcSEcCtD
Dabigatran etexilate—Bone disorder—Epirubicin—liver cancer	0.000363	0.00455	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Epirubicin—liver cancer	0.00036	0.00452	CcSEcCtD
Dabigatran etexilate—Anaemia—Sorafenib—liver cancer	0.000358	0.0045	CcSEcCtD
Dabigatran etexilate—Angioedema—Sorafenib—liver cancer	0.000354	0.00445	CcSEcCtD
Dabigatran etexilate—Syncope—Sorafenib—liver cancer	0.000348	0.00436	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Epirubicin—liver cancer	0.000346	0.00435	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Sorafenib—liver cancer	0.000341	0.00428	CcSEcCtD
Dabigatran etexilate—Cough—Sorafenib—liver cancer	0.000338	0.00425	CcSEcCtD
Dabigatran etexilate—Bone disorder—Doxorubicin—liver cancer	0.000336	0.00421	CcSEcCtD
Dabigatran etexilate—Rectal haemorrhage—Doxorubicin—liver cancer	0.000336	0.00421	CcSEcCtD
Dabigatran etexilate—Hypertension—Sorafenib—liver cancer	0.000335	0.0042	CcSEcCtD
Dabigatran etexilate—Hyperbilirubinaemia—Doxorubicin—liver cancer	0.000333	0.00419	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Epirubicin—liver cancer	0.000332	0.00416	CcSEcCtD
Dabigatran etexilate—Arthralgia—Sorafenib—liver cancer	0.00033	0.00414	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.000328	0.00411	CcSEcCtD
Dabigatran etexilate—Blood bilirubin increased—Doxorubicin—liver cancer	0.00032	0.00402	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Sorafenib—liver cancer	0.000316	0.00397	CcSEcCtD
Dabigatran etexilate—Infection—Sorafenib—liver cancer	0.000314	0.00395	CcSEcCtD
Dabigatran etexilate—Shock—Sorafenib—liver cancer	0.000311	0.00391	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Sorafenib—liver cancer	0.00031	0.00389	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Sorafenib—liver cancer	0.00031	0.00389	CcSEcCtD
Dabigatran etexilate—Skin disorder—Sorafenib—liver cancer	0.000307	0.00386	CcSEcCtD
Dabigatran etexilate—Musculoskeletal pain—Doxorubicin—liver cancer	0.000307	0.00385	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Epirubicin—liver cancer	0.000299	0.00376	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Epirubicin—liver cancer	0.000296	0.00372	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Sorafenib—liver cancer	0.000288	0.00362	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Sorafenib—liver cancer	0.000282	0.00354	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Sorafenib—liver cancer	0.000278	0.0035	CcSEcCtD
Dabigatran etexilate—Oesophagitis—Doxorubicin—liver cancer	0.000277	0.00348	CcSEcCtD
Dabigatran etexilate—Ecchymosis—Doxorubicin—liver cancer	0.000274	0.00344	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Sorafenib—liver cancer	0.000273	0.00343	CcSEcCtD
Dabigatran etexilate—Fatigue—Sorafenib—liver cancer	0.000273	0.00342	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Epirubicin—liver cancer	0.000272	0.00342	CcSEcCtD
Dabigatran etexilate—Constipation—Sorafenib—liver cancer	0.00027	0.0034	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Epirubicin—liver cancer	0.000262	0.00329	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Sorafenib—liver cancer	0.000259	0.00325	CcSEcCtD
Dabigatran etexilate—Hepatic function abnormal—Doxorubicin—liver cancer	0.000252	0.00316	CcSEcCtD
Dabigatran etexilate—Urticaria—Sorafenib—liver cancer	0.000251	0.00316	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Sorafenib—liver cancer	0.00025	0.00314	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Epirubicin—liver cancer	0.000244	0.00306	CcSEcCtD
Dabigatran etexilate—Cardiac failure congestive—Doxorubicin—liver cancer	0.000243	0.00305	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Epirubicin—liver cancer	0.000238	0.00299	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Epirubicin—liver cancer	0.000238	0.00299	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Epirubicin—liver cancer	0.000238	0.00299	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Sorafenib—liver cancer	0.000233	0.00293	CcSEcCtD
Dabigatran etexilate—Asthenia—Sorafenib—liver cancer	0.000227	0.00285	CcSEcCtD
Dabigatran etexilate—Cardiac failure—Doxorubicin—liver cancer	0.000225	0.00283	CcSEcCtD
Dabigatran etexilate—Pruritus—Sorafenib—liver cancer	0.000224	0.00281	CcSEcCtD
Dabigatran etexilate—Gastrointestinal haemorrhage—Doxorubicin—liver cancer	0.00022	0.00276	CcSEcCtD
Dabigatran etexilate—Pain in extremity—Doxorubicin—liver cancer	0.00022	0.00276	CcSEcCtD
Dabigatran etexilate—Osteoarthritis—Doxorubicin—liver cancer	0.00022	0.00276	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Epirubicin—liver cancer	0.00022	0.00276	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Epirubicin—liver cancer	0.000217	0.00273	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Sorafenib—liver cancer	0.000216	0.00272	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Epirubicin—liver cancer	0.000214	0.00269	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Epirubicin—liver cancer	0.000213	0.00267	CcSEcCtD
Dabigatran etexilate—Gastritis—Epirubicin—liver cancer	0.00021	0.00264	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Epirubicin—liver cancer	0.00021	0.00263	CcSEcCtD
Dabigatran etexilate—Dizziness—Sorafenib—liver cancer	0.000209	0.00263	CcSEcCtD
Dabigatran etexilate—Influenza—Epirubicin—liver cancer	0.000206	0.00258	CcSEcCtD
Dabigatran etexilate—Dysphagia—Epirubicin—liver cancer	0.000206	0.00258	CcSEcCtD
Dabigatran etexilate—Liver function test abnormal—Doxorubicin—liver cancer	0.000203	0.00255	CcSEcCtD
Dabigatran etexilate—Vomiting—Sorafenib—liver cancer	0.000201	0.00253	CcSEcCtD
Dabigatran etexilate—Abdominal pain upper—Doxorubicin—liver cancer	0.000201	0.00252	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Epirubicin—liver cancer	0.0002	0.00251	CcSEcCtD
Dabigatran etexilate—Rash—Sorafenib—liver cancer	0.000199	0.0025	CcSEcCtD
Dabigatran etexilate—Dermatitis—Sorafenib—liver cancer	0.000199	0.0025	CcSEcCtD
Dabigatran etexilate—Aspartate aminotransferase increased—Doxorubicin—liver cancer	0.000198	0.00249	CcSEcCtD
Dabigatran etexilate—Headache—Sorafenib—liver cancer	0.000198	0.00249	CcSEcCtD
Dabigatran etexilate—Bronchitis—Epirubicin—liver cancer	0.000198	0.00248	CcSEcCtD
Dabigatran etexilate—Nasopharyngitis—Doxorubicin—liver cancer	0.000197	0.00247	CcSEcCtD
Dabigatran etexilate—Gastritis—Doxorubicin—liver cancer	0.000195	0.00245	CcSEcCtD
Dabigatran etexilate—Alanine aminotransferase increased—Doxorubicin—liver cancer	0.000194	0.00244	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Epirubicin—liver cancer	0.000191	0.0024	CcSEcCtD
Dabigatran etexilate—Dysphagia—Doxorubicin—liver cancer	0.00019	0.00239	CcSEcCtD
Dabigatran etexilate—Influenza—Doxorubicin—liver cancer	0.00019	0.00239	CcSEcCtD
Dabigatran etexilate—Nausea—Sorafenib—liver cancer	0.000188	0.00236	CcSEcCtD
Dabigatran etexilate—Angina pectoris—Doxorubicin—liver cancer	0.000185	0.00233	CcSEcCtD
Dabigatran etexilate—Pneumonia—Epirubicin—liver cancer	0.000184	0.00231	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Epirubicin—liver cancer	0.000183	0.0023	CcSEcCtD
Dabigatran etexilate—Infestation—Epirubicin—liver cancer	0.000183	0.0023	CcSEcCtD
Dabigatran etexilate—Bronchitis—Doxorubicin—liver cancer	0.000183	0.0023	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Epirubicin—liver cancer	0.000178	0.00224	CcSEcCtD
Dabigatran etexilate—Upper respiratory tract infection—Doxorubicin—liver cancer	0.000177	0.00222	CcSEcCtD
Dabigatran etexilate—Haematuria—Epirubicin—liver cancer	0.000175	0.00219	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Epirubicin—liver cancer	0.000173	0.00218	CcSEcCtD
Dabigatran etexilate—ABCB1—liver—liver cancer	0.000173	0.00238	CbGeAlD
Dabigatran etexilate—Epistaxis—Epirubicin—liver cancer	0.000173	0.00217	CcSEcCtD
Dabigatran etexilate—Sinusitis—Epirubicin—liver cancer	0.000172	0.00216	CcSEcCtD
Dabigatran etexilate—Pneumonia—Doxorubicin—liver cancer	0.000171	0.00214	CcSEcCtD
Dabigatran etexilate—Infestation NOS—Doxorubicin—liver cancer	0.00017	0.00213	CcSEcCtD
Dabigatran etexilate—Infestation—Doxorubicin—liver cancer	0.00017	0.00213	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Epirubicin—liver cancer	0.000165	0.00208	CcSEcCtD
Dabigatran etexilate—Urinary tract infection—Doxorubicin—liver cancer	0.000165	0.00207	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Epirubicin—liver cancer	0.000165	0.00207	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Epirubicin—liver cancer	0.000162	0.00204	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Epirubicin—liver cancer	0.000162	0.00204	CcSEcCtD
Dabigatran etexilate—Haematuria—Doxorubicin—liver cancer	0.000162	0.00203	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Epirubicin—liver cancer	0.000162	0.00203	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Epirubicin—liver cancer	0.000161	0.00203	CcSEcCtD
Dabigatran etexilate—Hepatobiliary disease—Doxorubicin—liver cancer	0.00016	0.00201	CcSEcCtD
Dabigatran etexilate—Epistaxis—Doxorubicin—liver cancer	0.00016	0.00201	CcSEcCtD
Dabigatran etexilate—Sinusitis—Doxorubicin—liver cancer	0.000159	0.002	CcSEcCtD
Dabigatran etexilate—Haemoglobin—Doxorubicin—liver cancer	0.000153	0.00192	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Epirubicin—liver cancer	0.000153	0.00192	CcSEcCtD
Dabigatran etexilate—Haemorrhage—Doxorubicin—liver cancer	0.000152	0.00191	CcSEcCtD
Dabigatran etexilate—Urinary tract disorder—Doxorubicin—liver cancer	0.00015	0.00189	CcSEcCtD
Dabigatran etexilate—Oedema peripheral—Doxorubicin—liver cancer	0.00015	0.00188	CcSEcCtD
Dabigatran etexilate—Connective tissue disorder—Doxorubicin—liver cancer	0.00015	0.00188	CcSEcCtD
Dabigatran etexilate—Angiopathy—Epirubicin—liver cancer	0.000149	0.00187	CcSEcCtD
Dabigatran etexilate—Urethral disorder—Doxorubicin—liver cancer	0.000149	0.00187	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Epirubicin—liver cancer	0.000149	0.00187	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Epirubicin—liver cancer	0.000148	0.00186	CcSEcCtD
Dabigatran etexilate—Malnutrition—Epirubicin—liver cancer	0.000143	0.0018	CcSEcCtD
Dabigatran etexilate—Cardiac disorder—Doxorubicin—liver cancer	0.000141	0.00177	CcSEcCtD
Dabigatran etexilate—Flatulence—Epirubicin—liver cancer	0.000141	0.00177	CcSEcCtD
Dabigatran etexilate—Back pain—Epirubicin—liver cancer	0.000139	0.00174	CcSEcCtD
Dabigatran etexilate—Angiopathy—Doxorubicin—liver cancer	0.000138	0.00173	CcSEcCtD
Dabigatran etexilate—Immune system disorder—Doxorubicin—liver cancer	0.000137	0.00173	CcSEcCtD
Dabigatran etexilate—Mediastinal disorder—Doxorubicin—liver cancer	0.000137	0.00172	CcSEcCtD
Dabigatran etexilate—Malnutrition—Doxorubicin—liver cancer	0.000133	0.00166	CcSEcCtD
Dabigatran etexilate—Anaemia—Epirubicin—liver cancer	0.000132	0.00166	CcSEcCtD
Dabigatran etexilate—Flatulence—Doxorubicin—liver cancer	0.000131	0.00164	CcSEcCtD
Dabigatran etexilate—Syncope—Epirubicin—liver cancer	0.000128	0.00161	CcSEcCtD
Dabigatran etexilate—Back pain—Doxorubicin—liver cancer	0.000128	0.00161	CcSEcCtD
Dabigatran etexilate—Palpitations—Epirubicin—liver cancer	0.000127	0.00159	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Epirubicin—liver cancer	0.000126	0.00158	CcSEcCtD
Dabigatran etexilate—Cough—Epirubicin—liver cancer	0.000125	0.00157	CcSEcCtD
Dabigatran etexilate—Hypertension—Epirubicin—liver cancer	0.000124	0.00155	CcSEcCtD
Dabigatran etexilate—Anaemia—Doxorubicin—liver cancer	0.000122	0.00154	CcSEcCtD
Dabigatran etexilate—Arthralgia—Epirubicin—liver cancer	0.000122	0.00153	CcSEcCtD
Dabigatran etexilate—Chest pain—Epirubicin—liver cancer	0.000122	0.00153	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.000121	0.00152	CcSEcCtD
Dabigatran etexilate—Syncope—Doxorubicin—liver cancer	0.000119	0.00149	CcSEcCtD
Dabigatran etexilate—Palpitations—Doxorubicin—liver cancer	0.000117	0.00147	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Epirubicin—liver cancer	0.000117	0.00147	CcSEcCtD
Dabigatran etexilate—Loss of consciousness—Doxorubicin—liver cancer	0.000116	0.00146	CcSEcCtD
Dabigatran etexilate—Infection—Epirubicin—liver cancer	0.000116	0.00146	CcSEcCtD
Dabigatran etexilate—Cough—Doxorubicin—liver cancer	0.000116	0.00145	CcSEcCtD
Dabigatran etexilate—Shock—Epirubicin—liver cancer	0.000115	0.00144	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Epirubicin—liver cancer	0.000115	0.00144	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Epirubicin—liver cancer	0.000114	0.00144	CcSEcCtD
Dabigatran etexilate—Hypertension—Doxorubicin—liver cancer	0.000114	0.00144	CcSEcCtD
Dabigatran etexilate—Skin disorder—Epirubicin—liver cancer	0.000114	0.00143	CcSEcCtD
Dabigatran etexilate—Chest pain—Doxorubicin—liver cancer	0.000113	0.00142	CcSEcCtD
Dabigatran etexilate—Arthralgia—Doxorubicin—liver cancer	0.000113	0.00142	CcSEcCtD
Dabigatran etexilate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.000112	0.00141	CcSEcCtD
Dabigatran etexilate—Hypotension—Epirubicin—liver cancer	0.000109	0.00137	CcSEcCtD
Dabigatran etexilate—Anaphylactic shock—Doxorubicin—liver cancer	0.000108	0.00136	CcSEcCtD
Dabigatran etexilate—Infection—Doxorubicin—liver cancer	0.000107	0.00135	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Epirubicin—liver cancer	0.000106	0.00134	CcSEcCtD
Dabigatran etexilate—Shock—Doxorubicin—liver cancer	0.000106	0.00134	CcSEcCtD
Dabigatran etexilate—Nervous system disorder—Doxorubicin—liver cancer	0.000106	0.00133	CcSEcCtD
Dabigatran etexilate—Thrombocytopenia—Doxorubicin—liver cancer	0.000106	0.00133	CcSEcCtD
Dabigatran etexilate—Skin disorder—Doxorubicin—liver cancer	0.000105	0.00132	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Epirubicin—liver cancer	0.000104	0.00131	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Epirubicin—liver cancer	0.000103	0.00129	CcSEcCtD
Dabigatran etexilate—Hypotension—Doxorubicin—liver cancer	0.000101	0.00127	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Epirubicin—liver cancer	0.000101	0.00127	CcSEcCtD
Dabigatran etexilate—Fatigue—Epirubicin—liver cancer	0.000101	0.00127	CcSEcCtD
Dabigatran etexilate—Constipation—Epirubicin—liver cancer	9.99e-05	0.00126	CcSEcCtD
Dabigatran etexilate—Musculoskeletal discomfort—Doxorubicin—liver cancer	9.85e-05	0.00124	CcSEcCtD
Dabigatran etexilate—Dyspnoea—Doxorubicin—liver cancer	9.64e-05	0.00121	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Epirubicin—liver cancer	9.56e-05	0.0012	CcSEcCtD
Dabigatran etexilate—Dyspepsia—Doxorubicin—liver cancer	9.52e-05	0.0012	CcSEcCtD
Dabigatran etexilate—Gastrointestinal disorder—Doxorubicin—liver cancer	9.34e-05	0.00117	CcSEcCtD
Dabigatran etexilate—Fatigue—Doxorubicin—liver cancer	9.32e-05	0.00117	CcSEcCtD
Dabigatran etexilate—Urticaria—Epirubicin—liver cancer	9.29e-05	0.00117	CcSEcCtD
Dabigatran etexilate—Constipation—Doxorubicin—liver cancer	9.25e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Epirubicin—liver cancer	9.24e-05	0.00116	CcSEcCtD
Dabigatran etexilate—Gastrointestinal pain—Doxorubicin—liver cancer	8.84e-05	0.00111	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Epirubicin—liver cancer	8.61e-05	0.00108	CcSEcCtD
Dabigatran etexilate—Urticaria—Doxorubicin—liver cancer	8.59e-05	0.00108	CcSEcCtD
Dabigatran etexilate—Abdominal pain—Doxorubicin—liver cancer	8.55e-05	0.00107	CcSEcCtD
Dabigatran etexilate—Asthenia—Epirubicin—liver cancer	8.39e-05	0.00105	CcSEcCtD
Dabigatran etexilate—Pruritus—Epirubicin—liver cancer	8.27e-05	0.00104	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Epirubicin—liver cancer	8e-05	0.001	CcSEcCtD
Dabigatran etexilate—Hypersensitivity—Doxorubicin—liver cancer	7.97e-05	0.001	CcSEcCtD
Dabigatran etexilate—Asthenia—Doxorubicin—liver cancer	7.76e-05	0.000974	CcSEcCtD
Dabigatran etexilate—Dizziness—Epirubicin—liver cancer	7.73e-05	0.000971	CcSEcCtD
Dabigatran etexilate—Pruritus—Doxorubicin—liver cancer	7.65e-05	0.000961	CcSEcCtD
Dabigatran etexilate—Vomiting—Epirubicin—liver cancer	7.43e-05	0.000933	CcSEcCtD
Dabigatran etexilate—Diarrhoea—Doxorubicin—liver cancer	7.4e-05	0.000929	CcSEcCtD
Dabigatran etexilate—Rash—Epirubicin—liver cancer	7.37e-05	0.000925	CcSEcCtD
Dabigatran etexilate—Dermatitis—Epirubicin—liver cancer	7.36e-05	0.000925	CcSEcCtD
Dabigatran etexilate—Headache—Epirubicin—liver cancer	7.32e-05	0.00092	CcSEcCtD
Dabigatran etexilate—Dizziness—Doxorubicin—liver cancer	7.15e-05	0.000898	CcSEcCtD
Dabigatran etexilate—Nausea—Epirubicin—liver cancer	6.94e-05	0.000872	CcSEcCtD
Dabigatran etexilate—Vomiting—Doxorubicin—liver cancer	6.88e-05	0.000864	CcSEcCtD
Dabigatran etexilate—Rash—Doxorubicin—liver cancer	6.82e-05	0.000856	CcSEcCtD
Dabigatran etexilate—Dermatitis—Doxorubicin—liver cancer	6.81e-05	0.000856	CcSEcCtD
Dabigatran etexilate—Headache—Doxorubicin—liver cancer	6.78e-05	0.000851	CcSEcCtD
Dabigatran etexilate—Nausea—Doxorubicin—liver cancer	6.42e-05	0.000807	CcSEcCtD
Dabigatran etexilate—F2—Hemostasis—CSF2—liver cancer	3.59e-05	0.000393	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GLUL—liver cancer	3.45e-05	0.000377	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CPT1B—liver cancer	3.45e-05	0.000377	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SHC3—liver cancer	3.37e-05	0.000368	CbGpPWpGaD
Dabigatran etexilate—F2—Regulation of Actin Cytoskeleton—PIK3CA—liver cancer	3.35e-05	0.000367	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—liver cancer	3.34e-05	0.000365	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NR1H4—liver cancer	3.33e-05	0.000364	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTP1—liver cancer	3.28e-05	0.000359	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—JUN—liver cancer	3.28e-05	0.000358	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTA3—liver cancer	3.27e-05	0.000358	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—HMOX1—liver cancer	3.24e-05	0.000354	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—VEGFA—liver cancer	3.13e-05	0.000342	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC11A2—liver cancer	3.06e-05	0.000335	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—GGT1—liver cancer	3.04e-05	0.000332	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—NRF2 pathway—TGFB1—liver cancer	3.03e-05	0.000332	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—IGF2—liver cancer	3.03e-05	0.000331	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—GSTM1—liver cancer	3.02e-05	0.00033	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTA4—liver cancer	2.99e-05	0.000327	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ABL1—liver cancer	2.93e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—SLC40A1—liver cancer	2.92e-05	0.00032	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—CASP3—liver cancer	2.92e-05	0.000319	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—IL2—liver cancer	2.92e-05	0.000319	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTA2—liver cancer	2.92e-05	0.000319	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—MAPK14—liver cancer	2.91e-05	0.000318	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—TGFB1—liver cancer	2.87e-05	0.000314	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—VEGFA—liver cancer	2.86e-05	0.000313	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—CYP1A1—liver cancer	2.86e-05	0.000313	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTA1—liver cancer	2.81e-05	0.000308	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GLUL—liver cancer	2.81e-05	0.000307	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CPT1B—liver cancer	2.81e-05	0.000307	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ANXA2—liver cancer	2.8e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ATP7B—liver cancer	2.8e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—F2—G alpha (q) signalling events—PIK3CA—liver cancer	2.8e-05	0.000306	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—NAT2—liver cancer	2.78e-05	0.000304	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—liver cancer	2.72e-05	0.000298	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NR1H4—liver cancer	2.7e-05	0.000296	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CG—liver cancer	2.7e-05	0.000295	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALDOB—liver cancer	2.67e-05	0.000292	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—MTHFR—liver cancer	2.67e-05	0.000292	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTA3—liver cancer	2.66e-05	0.000291	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—NR1H4—liver cancer	2.65e-05	0.00029	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARA—liver cancer	2.62e-05	0.000286	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—FST—liver cancer	2.62e-05	0.000286	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PRKCE—liver cancer	2.57e-05	0.000281	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CRABP1—liver cancer	2.54e-05	0.000278	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—liver cancer	2.51e-05	0.000275	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—liver cancer	2.5e-05	0.000273	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TRIO—liver cancer	2.49e-05	0.000273	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—VEGFA—liver cancer	2.48e-05	0.000271	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—PIK3CA—liver cancer	2.45e-05	0.000267	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTA4—liver cancer	2.43e-05	0.000266	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCR4—liver cancer	2.39e-05	0.000262	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—CYP1A1—liver cancer	2.38e-05	0.00026	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CD—liver cancer	2.37e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTA2—liver cancer	2.37e-05	0.000259	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—SERPINE1—liver cancer	2.35e-05	0.000257	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—ALB—liver cancer	2.34e-05	0.000256	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PRKCE—liver cancer	2.33e-05	0.000255	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—liver cancer	2.31e-05	0.000253	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTA1—liver cancer	2.29e-05	0.00025	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TGFB1—liver cancer	2.28e-05	0.000249	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—CSF2—liver cancer	2.27e-05	0.000248	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—NAT2—liver cancer	2.26e-05	0.000247	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CG—liver cancer	2.24e-05	0.000245	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HPGDS—liver cancer	2.22e-05	0.000243	CbGpPWpGaD
Dabigatran etexilate—F2—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—liver cancer	2.21e-05	0.000242	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK14—liver cancer	2.21e-05	0.000241	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARA—liver cancer	2.17e-05	0.000238	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALDOB—liver cancer	2.17e-05	0.000237	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—liver cancer	2.16e-05	0.000237	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PPARG—liver cancer	2.16e-05	0.000236	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Allograft Rejection—TNF—liver cancer	2.12e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—UGDH—liver cancer	2.12e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—RAF1—liver cancer	2.12e-05	0.000232	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CRABP1—liver cancer	2.07e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CB—liver cancer	2.07e-05	0.000226	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—CSF2—liver cancer	2.06e-05	0.000225	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—APC—liver cancer	2.05e-05	0.000224	CbGpPWpGaD
Dabigatran etexilate—F2—Platelet activation, signaling and aggregation—AKT1—liver cancer	2e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—EPT1—liver cancer	2e-05	0.000218	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSMA4—liver cancer	1.98e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PSMD10—liver cancer	1.98e-05	0.000217	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CD—liver cancer	1.97e-05	0.000215	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—ALB—liver cancer	1.94e-05	0.000213	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GOT2—liver cancer	1.93e-05	0.000211	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—IL2—liver cancer	1.9e-05	0.000208	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—TAT—liver cancer	1.89e-05	0.000207	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ADAM17—liver cancer	1.89e-05	0.000207	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—MMP2—liver cancer	1.88e-05	0.000206	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—liver cancer	1.86e-05	0.000204	CbGpPWpGaD
Dabigatran etexilate—ABCB1—HIF-1-alpha transcription factor network—AKT1—liver cancer	1.83e-05	0.0002	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP2E1—liver cancer	1.81e-05	0.000198	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HPGDS—liver cancer	1.81e-05	0.000198	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—liver cancer	1.8e-05	0.000196	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSMA4—liver cancer	1.78e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PSMD10—liver cancer	1.78e-05	0.000194	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CB—liver cancer	1.72e-05	0.000188	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CG—liver cancer	1.71e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYCS—liver cancer	1.7e-05	0.000186	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GGT1—liver cancer	1.66e-05	0.000182	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GOT1—liver cancer	1.66e-05	0.000182	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—liver cancer	1.64e-05	0.000179	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—ALB—liver cancer	1.62e-05	0.000177	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—VEGFA—liver cancer	1.61e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSMA4—liver cancer	1.61e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PSMD10—liver cancer	1.61e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—RAF1—liver cancer	1.61e-05	0.000176	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GOT2—liver cancer	1.57e-05	0.000171	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CG—liver cancer	1.55e-05	0.000169	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CD—liver cancer	1.5e-05	0.000164	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTP1—liver cancer	1.5e-05	0.000164	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TGFB1—liver cancer	1.48e-05	0.000162	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—HMOX1—liver cancer	1.47e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP2E1—liver cancer	1.47e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—liver cancer	1.47e-05	0.000161	CbGpPWpGaD
Dabigatran etexilate—F2—Metabolism of proteins—CTNNB1—liver cancer	1.44e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—liver cancer	1.44e-05	0.000158	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—liver cancer	1.43e-05	0.000156	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—liver cancer	1.4e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—liver cancer	1.4e-05	0.000153	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—liver cancer	1.39e-05	0.000152	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYCS—liver cancer	1.38e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PRKCE—liver cancer	1.38e-05	0.000151	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—GSTM1—liver cancer	1.37e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—KRAS—liver cancer	1.37e-05	0.00015	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CD—liver cancer	1.36e-05	0.000149	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—liver cancer	1.36e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GOT1—liver cancer	1.35e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GGT1—liver cancer	1.35e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—CYCS—liver cancer	1.35e-05	0.000148	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MAPK8—liver cancer	1.32e-05	0.000145	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CB—liver cancer	1.31e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IGF2—liver cancer	1.3e-05	0.000143	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—CYP1A1—liver cancer	1.3e-05	0.000142	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GLUL—liver cancer	1.29e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CPT1B—liver cancer	1.29e-05	0.000141	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—PIK3CA—liver cancer	1.26e-05	0.000138	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NR1H4—liver cancer	1.24e-05	0.000136	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—liver cancer	1.22e-05	0.000134	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA3—liver cancer	1.22e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—TP53—liver cancer	1.22e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CSF2—liver cancer	1.22e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—RAF1—liver cancer	1.22e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTP1—liver cancer	1.22e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—MTHFR—liver cancer	1.21e-05	0.000133	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—H2AFX—liver cancer	1.2e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—IL2—liver cancer	1.2e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—HMOX1—liver cancer	1.2e-05	0.000131	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARA—liver cancer	1.19e-05	0.00013	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CB—liver cancer	1.19e-05	0.00013	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—HMOX1—liver cancer	1.17e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—HRAS—liver cancer	1.17e-05	0.000128	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—liver cancer	1.13e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—liver cancer	1.12e-05	0.000123	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—GSTM1—liver cancer	1.12e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA4—liver cancer	1.12e-05	0.000122	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL2—liver cancer	1.09e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA2—liver cancer	1.09e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TERT—liver cancer	1.09e-05	0.000119	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—CYP1A1—liver cancer	1.06e-05	0.000116	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTA1—liver cancer	1.05e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—liver cancer	1.05e-05	0.000115	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—PIK3CA—liver cancer	1.05e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—liver cancer	1.04e-05	0.000114	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—NAT2—liver cancer	1.04e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—F2—Hemostasis—AKT1—liver cancer	1.03e-05	0.000113	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CG—liver cancer	1.02e-05	0.000112	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALDOB—liver cancer	9.94e-06	0.000109	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KDR—liver cancer	9.93e-06	0.000109	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—MTHFR—liver cancer	9.87e-06	0.000108	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK14—liver cancer	9.87e-06	0.000108	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PPARG—liver cancer	9.85e-06	0.000108	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARA—liver cancer	9.68e-06	0.000106	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—ESR1—liver cancer	9.68e-06	0.000106	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—liver cancer	9.55e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CRABP1—liver cancer	9.49e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—PPARA—liver cancer	9.48e-06	0.000104	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—liver cancer	9.24e-06	0.000101	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—APC—liver cancer	9.15e-06	0.0001	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CG—liver cancer	9.15e-06	0.0001	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CD—liver cancer	8.97e-06	9.81e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—ALB—liver cancer	8.86e-06	9.68e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—liver cancer	8.7e-06	9.51e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—BRAF—liver cancer	8.6e-06	9.4e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B15—Metabolism—AKT1—liver cancer	8.55e-06	9.35e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HPGDS—liver cancer	8.29e-06	9.07e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CG—liver cancer	8.29e-06	9.07e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CD—liver cancer	8.04e-06	8.79e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PPARG—liver cancer	8e-06	8.75e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—PIK3CA—liver cancer	7.97e-06	8.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—SERPINE1—liver cancer	7.96e-06	8.7e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—KRAS—liver cancer	7.87e-06	8.61e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CB—liver cancer	7.82e-06	8.55e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—liver cancer	7.81e-06	8.53e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSMD10—liver cancer	7.39e-06	8.08e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PSMA4—liver cancer	7.39e-06	8.08e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CD—liver cancer	7.29e-06	7.97e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—PIK3CA—liver cancer	7.23e-06	7.91e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—ALB—liver cancer	7.2e-06	7.87e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GOT2—liver cancer	7.19e-06	7.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—RAF1—liver cancer	7.18e-06	7.85e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—ALB—liver cancer	7.05e-06	7.71e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MTOR—liver cancer	7.01e-06	7.67e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CB—liver cancer	7.01e-06	7.67e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP2E1—liver cancer	6.76e-06	7.39e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—HRAS—liver cancer	6.69e-06	7.32e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1B—liver cancer	6.58e-06	7.19e-05	CbGpPWpGaD
Dabigatran etexilate—F2—GPCR downstream signaling—AKT1—liver cancer	6.51e-06	7.12e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CASP3—liver cancer	6.45e-06	7.05e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL2—liver cancer	6.44e-06	7.04e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—IL6—liver cancer	6.41e-06	7e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Transmembrane transport of small molecules—RAF1—liver cancer	6.37e-06	6.97e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CB—liver cancer	6.35e-06	6.95e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYCS—liver cancer	6.32e-06	6.92e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CCND1—liver cancer	6.28e-06	6.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—JUN—liver cancer	6.26e-06	6.85e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CTNNB1—liver cancer	6.22e-06	6.8e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GOT1—liver cancer	6.21e-06	6.79e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GGT1—liver cancer	6.21e-06	6.79e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MMP9—liver cancer	6.09e-06	6.66e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—CDKN1A—liver cancer	6.07e-06	6.64e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MAPK8—liver cancer	5.93e-06	6.48e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling by GPCR—AKT1—liver cancer	5.91e-06	6.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTP1—liver cancer	5.57e-06	6.1e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—HMOX1—liver cancer	5.5e-06	6.01e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—VEGFA—liver cancer	5.47e-06	5.98e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—STAT3—liver cancer	5.42e-06	5.92e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—GSTM1—liver cancer	5.12e-06	5.6e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—MYC—liver cancer	5.03e-06	5.5e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TGFB1—liver cancer	5.02e-06	5.49e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—CYP1A1—liver cancer	4.86e-06	5.31e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—PIK3CA—liver cancer	4.77e-06	5.21e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—KRAS—liver cancer	4.65e-06	5.09e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—MTHFR—liver cancer	4.53e-06	4.95e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARA—liver cancer	4.44e-06	4.86e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—PIK3CA—liver cancer	4.27e-06	4.67e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—TP53—liver cancer	4.13e-06	4.52e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—HRAS—liver cancer	3.95e-06	4.32e-05	CbGpPWpGaD
Dabigatran etexilate—UGT2B7—Metabolism—AKT1—liver cancer	3.89e-06	4.26e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—PIK3CA—liver cancer	3.87e-06	4.24e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CG—liver cancer	3.8e-06	4.16e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—IL6—liver cancer	3.78e-06	4.14e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PPARG—liver cancer	3.67e-06	4.01e-05	CbGpPWpGaD
Dabigatran etexilate—F2—Signaling Pathways—AKT1—liver cancer	3.49e-06	3.82e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CD—liver cancer	3.34e-06	3.66e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—ALB—liver cancer	3.3e-06	3.61e-05	CbGpPWpGaD
Dabigatran etexilate—UGT1A9—Metabolism—AKT1—liver cancer	3.16e-06	3.46e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CB—liver cancer	2.91e-06	3.19e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—PIK3CA—liver cancer	1.78e-06	1.94e-05	CbGpPWpGaD
Dabigatran etexilate—ABCB1—Metabolism—AKT1—liver cancer	1.45e-06	1.59e-05	CbGpPWpGaD
